Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)	Series E Warrants [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Series E Warrants [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Series E Warrants [Member] Preferred Stock [Member]	Series E Warrants [Member] Common Stock [Member]	Series E Warrants [Member] Additional Paid-in Capital [Member]	Series E Warrants [Member] Retained Earnings [Member]	Series E Warrants [Member] AOCI Attributable to Parent [Member]	Chief Executive Officer [Member] Preferred Stock [Member] Series C Preferred Stock [Member]	Chief Executive Officer [Member] Preferred Stock [Member] Series B Preferred Stock [Member]	Chief Executive Officer [Member] Preferred Stock [Member]	Chief Executive Officer [Member] Common Stock [Member]	Chief Executive Officer [Member] Additional Paid-in Capital [Member]	Chief Executive Officer [Member] Retained Earnings [Member]	Chief Executive Officer [Member] AOCI Attributable to Parent [Member]	Chief Executive Officer [Member]	Preferred Stock [Member] Series C Preferred Stock [Member]	Preferred Stock [Member] Series B Preferred Stock [Member]	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2017																		$ 7,271	$ 69,432	$ 57,380,256	$ (54,765,045)		$ 2,691,913
Balance (in shares) at Dec. 31, 2017																647,819	79,246		6,943,283
Preferred conversion to common shares pursuant to private placement agreement																		(6,479)					(6,479)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																(647,819)
Preferred conversion to common shares pursuant to private placement agreement (in shares)																			589,747
Preferred conversion to common shares pursuant to private placement agreement																			$ 5,897	582			0
Shares issued pursuant to the public offering																			$ 29,000	2,726,087			2,755,087
Shares issued (in shares)																			2,900,000
Investment pursuant to Helomics 20% acquisition																			$ 11,000	1,031,250			1,042,250
Investment pursuant to Helomics 20% acquisition (in shares)																			1,100,000
Warrant exercises				$ 558	$ 55,238
Warrant exercises (in shares)				55,796
Vesting Expense																				226,387			226,837
Net loss																					(1,760,022)		(1,760,022)
Balance at Mar. 31, 2018																		792	$ 118,040	61,622,067	(56,525,066)		5,215,833
Balance (in shares) at Mar. 31, 2018																	79,246		11,804,073
Balance at Dec. 31, 2018																		792	$ 140,917	63,019,708	(63,107,945)		53,472
Balance (in shares) at Dec. 31, 2018																	79,246		14,091,748
Preferred conversion to common shares pursuant to private placement agreement
Preferred conversion to common shares pursuant to private placement agreement (in shares)																			159,854
Preferred conversion to common shares pursuant to private placement agreement																			$ 1,599	88,401			90,000
Shares issued pursuant to the public offering											$ 781	$ 49,219			$ 50,000				$ 28,638	2,401,071			2,429,709
Shares issued (in shares)											78,125								2,863,750
Vesting Expense																				263,600			263,600
Net loss																					(3,293,184)		(3,293,184)
Shares issued in forbearance agreement																			$ 1,666	156,684			158,350
Shares issued in forbearance agreement (in shares)																			166,667
Warrants issued pursuant to CEO note payable																				318,058			318,058
Balance at Mar. 31, 2019																		$ 792	$ 173,601	$ 66,296,741	$ (66,401,129)		$ 70,005
Balance (in shares) at Mar. 31, 2019																	79,246		17,360,144